These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11745225)

  • 1. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder.
    Kim JH; Shariat SF; Kim IY; Menesses-Diaz A; Tokunaga H; Wheeler TM; Lerner SP
    Cancer; 2001 Sep; 92(6):1475-83. PubMed ID: 11745225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma.
    Shariat SF; Kim JH; Andrews B; Kattan MW; Wheeler TM; Kim IY; Lerner SP; Slawin KM
    Cancer; 2001 Dec; 92(12):2985-92. PubMed ID: 11753975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
    Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S
    J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.
    Byrne RR; Shariat SF; Brown R; Kattan MW; Morton RA JR; Wheeler TM; Lerner SP
    J Urol; 2001 May; 165(5):1473-9. PubMed ID: 11342899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The loss of expression of transforming growth factor-beta receptors correlates with the histopathologic tumor grade in bladder transitional cell carcinoma patients.
    Lee DH; Yang SC; Hong SJ; Chung BH; Chung HJ; Tokunaga H; Kim IY; Song YS; Lerner SP; Morton RA
    Yonsei Med J; 1999 Apr; 40(2):118-23. PubMed ID: 10333714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients.
    Tokunaga H; Lee DH; Kim IY; Wheeler TM; Lerner SP
    Clin Cancer Res; 1999 Sep; 5(9):2520-5. PubMed ID: 10499628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression.
    King ED; Matteson J; Jacobs SC; Kyprianou N
    J Urol; 1996 Jan; 155(1):316-20. PubMed ID: 7490878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
    Kang Y; Prentice MA; Mariano JM; Davarya S; Linnoila RI; Moody TW; Wakefield LM; Jakowlew SB
    Exp Lung Res; 2000 Dec; 26(8):685-707. PubMed ID: 11195465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
    Patry G; Hovington H; Larue H; Harel F; Fradet Y; Lacombe L
    Int J Cancer; 2008 Apr; 122(7):1592-7. PubMed ID: 18058798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens.
    Tokunaga H; Shariat SF; Green AE; Brown RM; Zhou JH; Benedict WF; Lerner SP
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):16-22. PubMed ID: 11516846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
    Shiina H; Igawa M; Nagami H; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T; Kawanishi M
    Cancer; 1996 Oct; 78(8):1762-74. PubMed ID: 8859190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy.
    Shariat SF; Menesses-Diaz A; Kim IY; Muramoto M; Wheeler TM; Slawin KM
    Urology; 2004 Jun; 63(6):1191-7. PubMed ID: 15183988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer.
    Matsumoto K; Irie A; Satoh T; Ishii J; Iwabuchi K; Iwamura M; Egawa S; Baba S
    Urology; 2007 Sep; 70(3):602-7. PubMed ID: 17688917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of HER2 protein overexpression in non-muscle-invasive bladder cancer with emphasis on tumour grade and recurrence].
    Janane A; Hajji F; Ismail TO; Elondo JC; Ghadouane M; Ameur A; Abbar M; Bouzidi A
    Actas Urol Esp; 2011 Apr; 35(4):189-94. PubMed ID: 21419519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.
    Novara G; De Marco V; Gottardo F; Dalpiaz O; Bouygues V; Galfano A; Martignoni G; Patard JJ; Artibani W; Ficarra V
    Cancer; 2007 Oct; 110(8):1715-22. PubMed ID: 17724728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
    Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
    J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth factors and oncogene products in transitional cell carcinoma.
    Nakanishi K; Kawai T; Suzuki M; Torikata C
    Mod Pathol; 1996 Mar; 9(3):292-7. PubMed ID: 8685230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease.
    Margulis V; Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    Clin Cancer Res; 2006 Dec; 12(24):7369-73. PubMed ID: 17189409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and functions of EGF, FGF and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells.
    De Boer WI; Houtsmuller AB; Izadifar V; Muscatelli-Groux B; Van der Kwast TH; Chopin DK
    Int J Cancer; 1997 Apr; 71(2):284-91. PubMed ID: 9139855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.